S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:OSMT

Osmotica Pharmaceuticals Stock Forecast, Price & News

$4.35
-0.15 (-3.33 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.31
Now: $4.35
$4.50
50-Day Range
$4.12
MA: $5.28
$6.12
52-Week Range
$2.81
Now: $4.35
$9.67
Volume642,995 shs
Average Volume574,205 shs
Market Capitalization$224.11 million
P/E RatioN/A
Dividend YieldN/A
Beta3.27
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

MarketRank

Overall MarketRank

1.08 out of 5 stars

Medical Sector

819th out of 1,557 stocks

Pharmaceutical Preparations Industry

393rd out of 638 stocks

Analyst Opinion: 3.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OSMT
CUSIPN/A
CIKN/A
Phone908-809-1300
Employees379

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240.03 million
Cash Flow$5.00 per share
Book Value$2.23 per share

Profitability

Net Income$-270,900,000.00

Miscellaneous

Market Cap$224.11 million
Next Earnings Date3/17/2021 (Estimated)
OptionableNot Optionable
$4.35
-0.15 (-3.33 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for OSMT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

How has Osmotica Pharmaceuticals' stock been impacted by Coronavirus?

Osmotica Pharmaceuticals' stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OSMT shares have decreased by 14.0% and is now trading at $4.35.
View which stocks have been most impacted by COVID-19
.

Is Osmotica Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Osmotica Pharmaceuticals stock.
View analyst ratings for Osmotica Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Osmotica Pharmaceuticals?

Wall Street analysts have given Osmotica Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Osmotica Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for Osmotica Pharmaceuticals
.

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) posted its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.06. The firm had revenue of $57.17 million for the quarter, compared to analyst estimates of $36.54 million. Osmotica Pharmaceuticals had a negative return on equity of 15.61% and a negative net margin of 73.47%.
View Osmotica Pharmaceuticals' earnings history
.

What price target have analysts set for OSMT?

4 Wall Street analysts have issued 1 year price targets for Osmotica Pharmaceuticals' stock. Their forecasts range from $4.00 to $12.00. On average, they anticipate Osmotica Pharmaceuticals' share price to reach $9.00 in the next year. This suggests a possible upside of 106.9% from the stock's current price.
View analysts' price targets for Osmotica Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Osmotica Pharmaceuticals' key competitors?

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), (CGC), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and (AZN).

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the following people:
  • Mr. Brian A. Markison, Chairman, Pres & CEO (Age 61, Pay $1.58M)
  • Mr. James D. Schaub, Exec. VP & COO (Age 38, Pay $696.5k)
  • Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55, Pay $711.1k)
  • Dr. Tina Marie deVries, Exec. VP of R&D (Age 59, Pay $711.1k)
  • Mr. Andrew J. Einhorn, Chief Financial Officer (Age 60)
  • Mr. Sergio Alegre, VP of Global Compliance
  • Mr. Jarret Miller, Exec. VP of HR

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

Who are Osmotica Pharmaceuticals' major shareholders?

Osmotica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.66%).
View institutional ownership trends for Osmotica Pharmaceuticals
.

Which major investors are buying Osmotica Pharmaceuticals stock?

OSMT stock was acquired by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC.
View insider buying and selling activity for Osmotica Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Osmotica Pharmaceuticals' stock price today?

One share of OSMT stock can currently be purchased for approximately $4.35.

How big of a company is Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals has a market capitalization of $224.11 million and generates $240.03 million in revenue each year. The company earns $-270,900,000.00 in net income (profit) each year or $0.25 on an earnings per share basis. Osmotica Pharmaceuticals employs 379 workers across the globe.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is www.osmotica.com.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.